

**REMARKS:**


A few constructive editorial changes have been made in the claims to bring them somewhat more into line with U.S. practice and requirements.

Applicants have cancelled all of the originally filed claims, 1-28. New claims 29-42 have been added to better encompass the full scope and breadth of the invention, notwithstanding Applicants' belief that the claims would have been allowable as originally filed.

Entry of the amendments and favorable action on the merits are all hereby respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

By:   
G. PATRICK SAGE, Attorney #37,710

Dated: May 19, 2005  
Customer No.: 25,666  
500 Columbia Plaza  
350 East Michigan Ave.  
Kalamazoo, MI 49007-3856  
(269) 382-0030

Enclosure: Listing of Claims and Postal Card Receipt

\*\*\*\*\*


**THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.**



**LISTING OF CLAIMS**

**CLAIMS 1-28 (canceled)**

29. (new) A compound of formula (I),



wherein :

- R<sub>1</sub> and R<sub>2</sub>, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,
- R<sub>3</sub> represents halogen, alkoxy, an optionally substituted aryl group or NR'<sub>1</sub>R'<sub>2</sub> wherein R'<sub>1</sub> and R'<sub>2</sub>, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,
- R<sub>4</sub> represents hydrogen or NR''<sub>1</sub>R''<sub>2</sub> wherein R''<sub>1</sub> and R''<sub>2</sub>, which are the same or different, represent hydrogen or alkyl or together with nitrogen carrying them form a heterocycle,

its enantiomers, diastereoisomers, tautomers and addition salts thereof with a pharmaceutically acceptable acid or base,

it being understood that :


- the term "alkyl" denotes linear or branched hydrocarbon chain having from 1 to 8 carbon atoms,
- the term "alkoxy" denotes alkyl-oxy wherein the alkyl chain is linear or branched and has from 1 to 8 carbon atoms,
- the term "aryl" denotes phenyl or naphthyl,

- the term "heterocycle" denotes a mono- or bi-cyclic system which has from 5 to 11 carbon atoms and which may contain, in addition to the nitrogen atom to which  $R_1R_2$ ,  $R'_1R'_2$  or  $R''_1R''_2$  are bonded, one or two further hetero atoms selected from oxygen, sulphur and nitrogen, it being possible for the heterocyclic system to be substituted by one, two or three alkyl groups,

- the term "substituted" associated with aryl indicates that the phenyl or naphthyl group is substituted by one, two or three identical or different groups selected from halogen, alkyl, alkoxy, polyhaloalkyl and hydroxy,

- "polyhaloalkyl" denotes a linear or branched carbon chain having from 1 to 3 carbon atoms and from 1 to 7 halogen atoms.

30. (new) A compound of Claim 29, which is represented by formula (I'),



31. (new) A compound of Claim 29, wherein  $NR_1R_2$  represents  $NH_2$ , di-*n*-propylamine or morpholine.

32. (new) A compound of Claim 30, wherein  $NR_1R_2$  represents  $NH_2$ , di-*n*-propylamine or morpholine.

33. (new) A compound of Claim 29, wherein  $R_3$  represents 3,4-dimethoxyphenyl, 3,5-dimethylmorpholine, thiomorpholine, azepine, perhydroquinoline, pyrrolidine or chlorine.

34. (new) A compound of Claim 30, wherein  $R_3$  represents 3,4-dimethoxyphenyl, 3,5-dimethylmorpholine, thiomorpholine, azepine, perhydroquinoline, pyrrolidine or chlorine.

35. (new) A compound of Claim 29, wherein R<sub>4</sub> represents hydrogen, morpholine or azepine.

36. (new) A compound of Claim 30, wherein R<sub>4</sub> represents hydrogen, morpholine or azepine.

5 37. (new) A compound of Claim 29 which is selected from :

2-(dipropylamino)-8-(4-thiomorpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-(1-azocanyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-((4 $\alpha$ ,8 $\alpha$ )-octahydro-1(2*H*)-quinolyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

10 8-((4 $\alpha$ ,8 $\alpha$ )-octahydro-1(2*H*)-quinolyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

6,8-di(1-azepanyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-(1-azepanyl)-2-(dipropylamino)-6-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-(1-azepanyl)-2,6-di(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

15 2-amino-8-[(3 $\alpha$ ,5 $\beta$ )-3,5-dimethylmorpholinyl]pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-amino-8-[(3 $\alpha$ ,5 $\alpha$ )-3,5-dimethylmorpholinyl]pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-[(3 $\alpha$ ,5 $\beta$ )-3,5-dimethylmorpholinyl]-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-[(3 $\alpha$ ,5 $\alpha$ )-3,5-dimethylmorpholinyl]-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

20 8-[(3 $\alpha$ ,5 $\alpha$ )-3,5-dimethylmorpholinyl]-2-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

2-amino-8-(1-azepanyl)-6-(4-morpholinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

8-chloro-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

25 2-(dipropylamino)-8-(1-pyrrolidinyl)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one,

and 8-(3,4-dimethoxyphenyl)-2-(dipropylamino)pyrido[3,4-*d*]pyrimidin-4(3*H*)-one.

38. (new) A method for treating a living animal body, including a human, afflicted with a condition selected from cancer, non-insulin-dependent, type II diabetes, obesity, hyperlipidaemia, hypercholesterolaemia and cardiovascular complications thereof,

arthrosis, and arterial hypertension, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 29 which is effective for alleviation of the condition.

5 39. (new) A method for treating a living animal body, including a human, afflicted with a condition selected from non-insulin-dependent, type II diabetes and cardiovascular complications thereof, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 29 which is effective for alleviation of the condition.

10 40. (new) A method for treating a living animal body, including a human, afflicted with cancer, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 29 which is effective for alleviation of cancer.

15 41. (new) A method for treating a living animal body, including a human, afflicted with arthrosis, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 29 which is effective for alleviation of arthrosis.

20 42. (new) A method for treating a living animal body, including a human, afflicted with arterial hypertension, comprising the step of administering to the living animal body, including a human, an amount of a compound of Claim 29 which is effective for alleviation of arterial hypertension.